Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
CKD tries to invalidate Celebrex patent completely
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Jun 4, 2014 13:07:23
Chong Kun Dang (CKD) filed its case to invalidate the patent of Celebrex on the composition of celecoxib on May 30.

CKD has already gotten marketing approval for its generic version of Celebrex in 2010. The patent on the substance of Celebrex expires in June 2015, but that on the composition is still good till 2019.

If CKD wins the case, it will roll out its generic version in June 2015. Currently more than twenty pharmaceutical companies got marketing approvals for their generic ones and more plan to have their generic Celebrex approved before March 2015.

European regulators sided with generic drug makers of Celebrex and the first generic version of Celebrex got approved in the U.S. on May 30. Celebrex sales were about 50 billion won last year.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com